# 返老还童感 (Rejuvenation)

[◀返回](./home.md)

**返老还童感** 可以描述为在某些化合物的药效残余期感受到的一种从轻微到极度的认知清爽感。返老还童感的症状通常包括持续的思维清晰度提高、情绪稳定性增加、平静感增加、[正念](/文档/正念.md)、[动机增强](/药效/动机增强.md)、[个人偏见抑制](/药效/个人偏见抑制.md)、[专注力强化](/药效/专注力强化.md)和[抑郁减轻](/药效/抑郁减轻.md)。在其最高程度上，返老还童的感觉可能变得如此强烈，以至于表现为深刻而压倒性的“重生”感。这种精神状态可能在物质药效消退后持续数小时到数月不等。

返老还童感最常在[中等](/文档/药物剂量分类.md#中等)[剂量](/文档/药物剂量分类.md)的[致幻剂](/文档/药物分类/致幻剂.md)化合物影响下被诱发，例如[迷幻剂](/文档/药物分类/迷幻剂.md)和[解离剂](/文档/药物分类/解离剂.md)。然而，它也可能在[共情剂](/文档/药物分类/共情剂.md)、[大麻类](/文档/药物分类/大麻类.md)和[冥想](/文档/冥想.md)的影响下发生，但程度较轻。

## 分析

有许多合法的科学研究已经得出结论，认为药物服用后可能会出现持久的精神益处。例如，已经证明氯胺酮即使以小剂量服用，对患有慢性抑郁症和双相情感障碍的患者也是有效的。研究表明，该药物的效果是立竿见影的或在2小时内显现，并且在缓解患者的抑郁和/或自杀症状方面是一致的，单次给药后可持续长达3天。

类似的例子包括一项研究，该研究观察到晚期癌症患者在使用赛洛西宾治疗六个月后，抑郁评分显著下降。[\[1\]](#cite_note-1) 2016年在英国进行了一项开放标签研究，旨在调查赛洛西宾治疗单相难治性抑郁症患者的可行性、安全性和有效性，结果令人鼓舞；尽管该研究规模较小，仅涉及12名患者，但其中7名患者在赛洛西宾治疗一周后符合缓解的正式标准，其中5名患者在三个月后仍处于抑郁缓解状态。[\[2\]](#cite_note-2)

## 体验报告

在我们的[体验索引](/药效/体验索引.md)中描述此效应的坊间报告包括：

* [Experience: 22mg 2C-B (oral) / 100ug 1P-LSD (sublingual) - My first time tripping alone (2 days in a row)](/报告/psychounautwiki/Experience:_22mg_2C-B_(oral)_/_100ug_1P-LSD_(sublingual)_-_My_first_time_tripping_alone_(2_days_in_a_row).md)
* [Experience: 32mg 2C-B - Bromo Mescaline](/报告/psychounautwiki/Experience:_32mg_2C-B_-_Bromo_Mescaline.md)
* [Experience:120µg LSD - First Bad Acid Trip, Psychosis](/报告/psychounautwiki/Experience:120µg_LSD_-_First_Bad_Acid_Trip,_Psychosis.md)
* [Experience:150mg MDMA + 20mg 2C-B - I designed it this way myself](/报告/psychounautwiki/Experience:150mg_MDMA_%2B_20mg_2C-B_-_I_designed_it_this_way_myself.md)
* [Experience:1g of stars and love](/报告/psychounautwiki/Experience:1g_of_stars_and_love.md)
* [Experience:2g Syrian rue + 1g Mimosa Hostilis - These voices are the building blocks of consciousness](/报告/psychounautwiki/Experience:2g_Syrian_rue_%2B_1g_Mimosa_Hostilis_-_These_voices_are_the_building_blocks_of_consciousness.md)
* [Experience:3 Grams of Mushrooms - Reset on my Life, Experiencing Satori and the Cosmic Perspective](/报告/psychounautwiki/Experience:3_Grams_of_Mushrooms_-_Reset_on_my_Life,_Experiencing_Satori_and_the_Cosmic_Perspective.md)
* [Experience:3.5g psilocybe cubensis - Relinquishing of Material Chains/Fear and Desolation](/报告/psychounautwiki/Experience:3.5g_psilocybe_cubensis_-_Relinquishing_of_Material_Chains/Fear_and_Desolation.md)
* [Experience:337mg DMT fumarate - A Day With DMT](/报告/psychounautwiki/Experience:337mg_DMT_fumarate_-_A_Day_With_DMT.md)
* [Experience:5.3g psilocybe cubensis - Dimensional Circumstance and the Fabric of Understanding](/报告/psychounautwiki/Experience:5.3g_psilocybe_cubensis_-_Dimensional_Circumstance_and_the_Fabric_of_Understanding.md)
* [Experience:50mg - How's the short-term memory?](/报告/psychounautwiki/Experience:50mg_-_How%27s_the_short-term_memory%3F.md)
* [Experience:5g Mushrooms - Failed attempt at a Terence Mckenna style trip.](/报告/psychounautwiki/Experience:5g_Mushrooms_-_Failed_attempt_at_a_Terence_Mckenna_style_trip..md)
* [Experience:800 seeds LSA - My First Trip Ever](/报告/psychounautwiki/Experience:800_seeds_LSA_-_My_First_Trip_Ever.md)
* [Experience:Mushrooms (~0.5 g) - Autonomous Voice](/报告/psychounautwiki/Experience:Mushrooms_(~0.5_g)_-_Autonomous_Voice.md)
* [Experience:Psilocybin Mushroom (0.16 g, Oral) - Dosage Independent Intensity](/报告/psychounautwiki/Experience:Psilocybin_Mushroom_(0.16_g,_Oral)_-_Dosage_Independent_Intensity.md)
* [Experience:Unknown Dose DOC (Insufflated) - Overdosing and Terifying Ego Death](/报告/psychounautwiki/Experience:Unknown_Dose_DOC_(Insufflated)_-_Overdosing_and_Terifying_Ego_Death.md)

## 另见

* [负责任的用药索引页](/文档/负责任的用药索引页.md)
* [主观效应索引](/药效/主观效应索引.md)
* [迷幻剂 - 主观效应](/文档/药物分类/迷幻剂.md#主观效应)
* [解离剂 - 主观效应](/文档/药物分类/解离剂.md#主观效应)
* [谵妄剂 - 主观效应](/文档/药物分类/谵妄剂.md#主观效应)

## 参考文献

1. [↑](#cite_ref-1) Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., Greer, G. R. (3 January 2011\). ["Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer"](http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/archgenpsychiatry.2010.116). *Archives of General Psychiatry*. **68** (1\): 71\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10\.1001/archgenpsychiatry.2010\.116](//doi.org/10.1001%2Farchgenpsychiatry.2010.116). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0003-990X](//www.worldcat.org/issn/0003-990X).
2. [↑](#cite_ref-2) Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., Nutt, D. J. (July 2016\). ["Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study"](https://linkinghub.elsevier.com/retrieve/pii/S2215036616300657). *The Lancet Psychiatry*. **3** (7\): 619–627\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10\.1016/S2215-0366(16\)30065-7](//doi.org/10.1016%2FS2215-0366%2816%2930065-7). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [2215-0366](//www.worldcat.org/issn/2215-0366).
